Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional

BIBTEX RIS

CURRENT PERSPECTIVES REGARDING THE IMMUNOLOGICAL INTERACTIONS BETWEEN APS AND SARS-COV-2

2021; Volume: 10; Issue: 1 Linguagem: Inglês

10.46344/jbino.2021.v010i01.07

2277-8330

Antonio de Padua Medeiros De Carvalho Neto., Leticia Azevedo Salgueiro., Lucas Emanuel Lemos Fontes, Silva Mata., Luís Gomes, Luiz Eduardo Canuto Neto Barros Thaynara Melo dos Anjos, Cristiane Monteiro da Cruz,

SARS-CoV-2 and COVID-19 Research

Autoimmune diseases are commonly known for their difficult diagnosis.Currently it is known that these pathologies arise as a result of a set of factors.Among them are the genetic and environmental factors, in addition to the failure of one's body immune system.The failure in the immune system is mainly associated with molecular mimicry which causes the defense cells to attack the body as an attempt to perform a biological protection.Furthermore, it is known that among the environmental factors, the viral infections stand out as potential triggers to the autoimmunity process, since viruses have several mechanisms to block the performance of regulatory T cells and induce the production of inflammatory cytokines.COVID-19 is an infectious viral disease caused by the SARS-CoV-2 virus.Patients infected with the virus are more susceptible to arterial and venous obstruction based on thrombotic fibrin.Thus, individuals infected with SARS-CoV-2 have an increased likelihood to develop the Antiphospholipid Antibody Syndrome (APS).APS is an autoimmune disease associated with the development of hypercoagulability, high serum levels of antiphospholipid antibody and is responsible for the occurrence of important thrombotic processes in individuals affected by the pathology.Furthermore, it is known that individuals with APS have a higher risk of suffering from acute myocardial infarction as a consequence of disease complications.The aim of this study is to evaluate the clinical and immunological characteristics of patients with antiphospholipid syndrome (APS) and to investigate its possible association with the SARS-CoV-2 virus.